A Drug Master File (DMF) is a confidential document submitted to the FDA that contains detailed information about a facility, process, or material used in the manufacturing, processing, packaging, or storing of a drug. The key feature of a DMF is that it allows a company to share proprietary information with the FDA without revealing trade secrets to other companies that rely on that same material or process. Think of it as a behind-the-scenes file that proves a component of a drug is safe and manufactured properly, without forcing the company that makes that component to hand its confidential data to competitors.
DMFs come up most often in the context of generic drugs, where one company manufactures an active ingredient and another company uses that ingredient to make a finished product. Instead of sharing proprietary manufacturing details directly, the ingredient manufacturer files a DMF with the FDA and grants the drug maker permission to reference it.
How a DMF Actually Works
A DMF is not an application for approval. Filing one doesn’t result in the FDA approving or disapproving the document itself. Instead, the DMF sits on file at the FDA, and its contents only get reviewed when another company references it in their own drug application, such as a New Drug Application (NDA) or an Abbreviated New Drug Application (ANDA) for a generic drug.
Here’s a practical example. A chemical company in India manufactures an active pharmaceutical ingredient (API) used in a common blood pressure medication. A generic drug company in the United States wants to use that API in its own version of the medication. The Indian manufacturer submits a DMF to the FDA containing full details about how the ingredient is synthesized, what quality controls are in place, what impurities might be present, and how the facility operates. The U.S. generic company then references that DMF in its ANDA, and the FDA reviews the relevant sections of the DMF as part of evaluating the generic drug application.
This system protects both parties. The API manufacturer doesn’t have to disclose trade secrets to the generic company. The generic company doesn’t have to independently generate all the data about the ingredient. And the FDA still gets full visibility into every component of the drug.
The Five Types of DMFs
The FDA categorizes DMFs into five types based on what information they contain:
- Type I: Manufacturing Site, Facilities, Operating Procedures, and Personnel. This type was used to describe a manufacturing facility’s capabilities and procedures. The FDA no longer accepts new Type I submissions, as this information is now captured through other regulatory mechanisms.
- Type II: Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product. This is by far the most common type. It covers the active ingredient itself, including how it’s made, tested, and stored. Most DMFs on file with the FDA are Type II.
- Type III: Packaging Material. This covers containers, closures, and other packaging components that come into contact with the drug product, along with data showing those materials are safe and compatible.
- Type IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation. Excipients are the inactive ingredients in a drug, things like fillers, binders, coatings, and preservatives. A Type IV DMF provides data on these components.
- Type V: FDA Accepted Reference Information. This is a catch-all for any information not covered by the other types.
Who Files a DMF and Why
DMFs are filed by companies that supply materials or services to drug manufacturers but don’t submit drug applications themselves. The most common filers are API manufacturers, excipient suppliers, packaging companies, and contract manufacturing organizations. These companies often serve multiple drug makers, so having a single DMF on file is far more efficient than providing the same proprietary information to every customer individually.
For the drug company submitting an NDA or ANDA, referencing a DMF simplifies the application process considerably. Rather than generating original data on every raw material and component, they can point the FDA to a DMF that already contains the necessary information. The DMF holder provides a “Letter of Authorization” granting the drug company permission to reference specific sections of the file, and only those authorized sections are reviewed.
What a DMF Contains
The specific contents depend on the type, but a typical Type II DMF for an active ingredient includes the chemical structure and properties of the substance, a step-by-step description of the manufacturing process, specifications for purity and quality, analytical methods used for testing, stability data showing how the substance holds up over time, and information about the manufacturing facility itself. The level of detail is extensive. The FDA expects enough information to independently evaluate whether the substance is consistently produced to an acceptable standard.
DMFs are living documents. Holders are expected to update them when manufacturing processes change, when new data becomes available, or when the FDA requests additional information. An outdated DMF can delay or jeopardize the approval of any drug application that references it, so keeping the file current is important for both the DMF holder and its customers.
DMFs vs. Drug Applications
One common point of confusion is the difference between a DMF and a drug application. A DMF does not seek approval for anything. It is purely a supporting document. You cannot market a drug or ingredient based on a DMF alone. The FDA does not “approve” a DMF in the way it approves an NDA. It reviews sections of the DMF only in connection with an active drug application, and its assessment applies only to that specific context.
This means a DMF can sit on file for years without ever being reviewed if no one references it. It also means the FDA might review the same DMF multiple times for different drug applications, potentially reaching different conclusions depending on the intended use.
How to Find DMFs on File
The FDA maintains a publicly available DMF database that lists the file number, holder name, DMF type, and subject of each submission. The actual contents remain confidential, but the database lets drug companies identify potential suppliers and verify that a DMF exists before entering a business relationship. You can search this database on the FDA’s website under the “Drug Master Files” section of the Center for Drug Evaluation and Research (CDER).
As of recent counts, there are tens of thousands of DMFs on file with the FDA, reflecting the global and highly specialized nature of pharmaceutical supply chains. The majority originate from companies based outside the United States, particularly in India and China, where much of the world’s API manufacturing takes place.